The US Food and Drug Administration (FDA) has confirmed that Symbicort (budesonide/formoterol) Inhalation Aerosol is worth being granted paediatric exclusivity. The six-month approval by the regulatory agency was occasioned by the results of a series of evaluations that were carried out in children aged six to twelve with asthma. Symbicort from AstraZeneca plc (ADR) (NYSE:AZN) has a common use in the US in the treatment of asthma for patients aged twelve years and older. It has also come in handy for adults who are safeguarding treatment of their chronic disruptive pulmonary diseases.

Symbicort has been approved in approximately 20 countries

The market seems to have embraced Symbicort despite the competition. Its approval in 20 countries after having been launched in Sweden in 2000 says it all. Its first approval was in the US in July 2006. Its approval is a significant milestone for AstraZeneca. Another of its main focus is therapy areas, the mentionable ones being oncology, inflammation, gastrointestinal, cardiovascular, and neuroscience areas.

In 2015, the company was able to reach more than 17 million patients. But notably, it has a bigger goal, the transformation of asthma and COPD treatment. It is quickly establishing core care strategies in meeting the unmet needs of specific patient populations. They are also into scientific advancements in disease modification

AstraZeneca’s overall performance

Currently, AstraZeneca has 1,265,000,000 shares outstanding. The Company has its operations in over 100 countries with various projects on board. Some of AstraZeneca’s more significant products in its pipeline are Bydureon, Xigduo XR, Bricanyl Turbuhaler,  Symbicort pMDI, Rhinocort, and metformin XR, among others

The company is currently working on a Toll-like receptor 9 (TLR-9) receptor agonist, which is expected to address imbalances in the immune system. Meanwhile, AstraZeneca’s stock was trading at $26.72, a fall of $0.56 or 2.05%.